Extended Data Fig. 2: Lack of β-catenin expression and activity in B-lymphoid cells.
(a-b) Immunohistochemical staining for β-catenin expression (brown, hematoxylin counterstain) in (a) human lymphoid tissues (left), including bone marrow (n = 7 tissues, biological replicates), spleen (n = 6 tissues, biological replicates), lymph node (n = 8 tissues, biological replicates), tonsil (n = 9 tissues, biological replicates) and (b) epithelial tissues (right), including colon (n = 7 tissues, biological replicates), liver (n = 9 tissues, biological replicates), pancreas (n = 12 tissues, biological replicates), kidney (n = 8 tissues, biological replicates), lung (n = 8 tissues, biological replicates) and skin (n = 7 tissues, biological replicates). Representative images are shown. Data derived from: https://www.proteinatlas.org/ENSG00000168036-CTNNB1/tissue#expression_summary (c-d) β-catenin expression was assessed by immunohistochemistry (brown) and using hematoxylin as counterstain (blue) on tissue microarrays from (c) B-lymphoid malignancies, including mantle cell lymphoma (n = 12 tumors, biological replicates), follicular lymphoma (n = 24 tumors, biological replicates), DLBCL (n = 24 tumors, biological replicates) and Hodgkin’s lymphoma (n = 24 tumors, biological replicates) as well as (d) epithelial cancers, including colon cancer (n = 12 tumors, biological replicates), lung cancer (n = 12 tumors, biological replicates) and malignant melanoma (n = 3 tumors, biological replicates). (e) Western blot analysis of β-catenin expression in cytoplasmic fractions of epithelial cancers, including lung and colon cancer, malignant melanoma, as well as B-lymphoid malignancies, including B-ALL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt’s, Hodgkin’s disease (HD) and multiple myeloma cell lines. β-tubulin and TBP were used to verify purity of cytoplasmic fractions.
